CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$55.79
−1.24%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+7.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jun 9, 2026 | High Katherine A · director | A-Award | 13,000 | $52 |
| Jun 9, 2026 | Greene John · director | A-Award | 13,000 | $52 |
| Jun 9, 2026 | Rommel Christian · director | A-Award | 13,000 | $52 |
| Jun 9, 2026 | Fardis Maria · director | A-Award | 13,000 | $52 |
| Jun 9, 2026 | Behbahani Ali · director | A-Award | 13,000 | $52 |
| Jun 9, 2026 | Morrison Briggs · director | A-Award | 13,000 | $52 |
| Jun 9, 2026 | George Simeon · director | A-Award | 13,000 | $52 |
| Jun 9, 2026 | Mahatme Sandesh · director | A-Award | 13,000 | $52 |
| Jun 9, 2026 | Treco Douglas A · director | A-Award | 13,000 | $52 |
| Jun 9, 2026 | Fleming Harold Edward · director | A-Award | 13,000 | $52 |
| Jun 2, 2026 | Patel Naimish · officer: Chief Medical Officer | A-Award | 22,000 | $0.00 |
| Jun 2, 2026 | KASINGER JAMES R. · officer: General Counsel and Secretary | A-Award | 17,000 | $0.00 |
| Jun 2, 2026 | Prasad Raju · officer: Chief Financial Officer | A-Award | 19,500 | $0.00 |
| Jun 1, 2026 | Patel Naimish · officer: Chief Medical Officer | M-Exempt | 10,000 | $0.00 |
| Jun 1, 2026 | Patel Naimish · officer: Chief Medical Officer | Sale | 3,786 | $56 |
| Mar 24, 2026 | Prasad Raju · officer: Chief Financial Officer | Sale | 3,708 | $47 |
| Mar 24, 2026 | Prasad Raju · officer: Chief Financial Officer | M-Exempt | 6,250 | $0.00 |
| Mar 24, 2026 | KASINGER JAMES R. · officer: General Counsel and Secretary | A-Award | 25,000 | $0.00 |
| Mar 24, 2026 | KASINGER JAMES R. · officer: General Counsel and Secretary | Sale | 3,182 | $47 |
| Mar 24, 2026 | Kulkarni Samarth · director, officer: Chief Executive Officer | A-Award | 114,249 | $46 |
| Mar 24, 2026 | Patel Naimish · officer: Chief Medical Officer | A-Award | 30,000 | $0.00 |
| Mar 24, 2026 | Kulkarni Samarth · director, officer: Chief Executive Officer | Sale | 10,020 | $47 |
| Mar 24, 2026 | Prasad Raju · officer: Chief Financial Officer | A-Award | 27,500 | $0.00 |
| Mar 24, 2026 | Kulkarni Samarth · director, officer: Chief Executive Officer | A-Award | 81,875 | $0.00 |
| Mar 24, 2026 | KASINGER JAMES R. · officer: General Counsel and Secretary | M-Exempt | 6,250 | $0.00 |
| Mar 24, 2026 | Prasad Raju · officer: Chief Financial Officer | A-Award | 38,499 | $46 |
| Mar 24, 2026 | Patel Naimish · officer: Chief Medical Officer | A-Award | 38,499 | $46 |
| Mar 24, 2026 | KASINGER JAMES R. · officer: General Counsel and Secretary | A-Award | 38,499 | $46 |
| Mar 24, 2026 | Kulkarni Samarth · director, officer: Chief Executive Officer | M-Exempt | 19,687 | $0.00 |
| Mar 17, 2026 | Prasad Raju · officer: Chief Financial Officer | M-Exempt | 6,875 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 161Increased 334Reduced 278Sold out 47
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ARK INVESTMENT MANAGEMENT LLC | Increased | 11,313,623 | May 12, 2026 |
| ARK Investment Management LLC | Reduced | 9,460,939 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 8,348,977 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 7,680,073 | May 13, 2026 |
| ORBIS ALLAN GRAY LTD | Increased | 6,106,011 | May 15, 2026 |
| Orbis Allan Gray Ltd | Reduced | 5,449,161 | Aug 14, 2026 |
| Capital World Investors | Increased | 4,749,525 | Aug 12, 2026 |
| CAPITAL WORLD INVESTORS | New Position | 4,725,037 | May 13, 2026 |
| STATE STREET CORP | Increased | 4,321,666 | Aug 7, 2026 |
| STATE STREET CORP | Increased | 3,982,500 | May 15, 2026 |
| GSK plc | Unchanged | 3,220,627 | Aug 13, 2026 |
| GSK PLC | Unchanged | 3,220,627 | May 14, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | Reduced | 2,952,595 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 2,509,915 | Aug 12, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 2,377,164 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 9, 2026